590 related articles for article (PubMed ID: 25378918)
1. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD.
Postma DS; Roche N; Colice G; Israel E; Martin RJ; van Aalderen WM; Grigg J; Burden A; Hillyer EV; von Ziegenweidt J; Gopalan G; Price D
Int J Chron Obstruct Pulmon Dis; 2014; 9():1163-86. PubMed ID: 25378918
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands.
van der Molen T; Postma DS; Martin RJ; Herings RM; Overbeek JA; Thomas V; Miglio C; Dekhuijzen R; Roche N; Guilbert T; Israel E; van Aalderen W; Hillyer EV; van Rysewyk S; Price DB
BMC Pulm Med; 2016 May; 16(1):80. PubMed ID: 27184175
[TBL] [Abstract][Full Text] [Related]
3. Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma.
van Aalderen WM; Grigg J; Guilbert TW; Roche N; Israel E; Martin RJ; Colice G; Postma DS; Hillyer EV; Burden A; Thomas V; von Ziegenweidt J; Price D
J Allergy Clin Immunol Pract; 2015; 3(5):721-31.e16. PubMed ID: 26032474
[TBL] [Abstract][Full Text] [Related]
4. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
[TBL] [Abstract][Full Text] [Related]
5. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma.
Price D; Thomas M; Haughney J; Lewis RA; Burden A; von Ziegenweidt J; Chisholm A; Hillyer EV; Corrigan CJ
Respir Med; 2013 Jul; 107(7):987-1000. PubMed ID: 23643486
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
7. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone.
Colice G; Martin RJ; Israel E; Roche N; Barnes N; Burden A; Polos P; Dorinsky P; Hillyer EV; Lee AJ; Chisholm A; von Ziegenweidt J; Barion F; Price D
J Allergy Clin Immunol; 2013 Jul; 132(1):45-54. PubMed ID: 23591272
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.
Singh D; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2017; 12():3263-3271. PubMed ID: 29138555
[TBL] [Abstract][Full Text] [Related]
9. Extrafine compared to non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma.
Cox CA; Boudewijn IM; Vroegop SJ; Schokker S; Lexmond AJ; Frijlink HW; Hagedoorn P; Vonk JM; Farenhorst MP; Ten Hacken NHT; Kerstjens HAM; Postma DS; van den Berge M
Respir Med; 2017 Sep; 130():35-42. PubMed ID: 29206631
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study.
Martin RJ; Price D; Roche N; Israel E; van Aalderen WM; Grigg J; Postma DS; Guilbert TW; Hillyer EV; Burden A; von Ziegenweidt J; Colice G
NPJ Prim Care Respir Med; 2014 Oct; 24():14081. PubMed ID: 25297072
[TBL] [Abstract][Full Text] [Related]
12. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
13. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
14. Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids.
Guilbert TW; Colice G; Grigg J; van Aalderen W; Martin RJ; Israel E; Postma DS; Roche N; Phipatanakul W; Hillyer EV; Evans JM; Dolovich MB; Price DB;
J Allergy Clin Immunol Pract; 2017; 5(4):1040-1049.e4. PubMed ID: 28110057
[TBL] [Abstract][Full Text] [Related]
15. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
Suh DC; Lau H; La HO; Choi IS; Geba GP
Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
[TBL] [Abstract][Full Text] [Related]
16. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
17. Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.
Price DB; Henley W; Cançado JED; Fabbri LM; Kerstjens HAM; Papi A; Roche N; Şen E; Singh D; Vogelmeier CF; Barille S; Nudo E; Carter V; Skinner D; Vella R; Georges G
Int J Chron Obstruct Pulmon Dis; 2022; 17():355-370. PubMed ID: 35210765
[TBL] [Abstract][Full Text] [Related]
18. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.
Morjaria JB; Rigby A; Morice AH
Lung; 2017 Jun; 195(3):281-288. PubMed ID: 28255905
[TBL] [Abstract][Full Text] [Related]
19. "Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD.
Vogelmeier C; Worth H; Buhl R; Criée CP; Lossi NS; Mailänder C; Kardos P
Int J Chron Obstruct Pulmon Dis; 2017; 12():487-494. PubMed ID: 28203072
[TBL] [Abstract][Full Text] [Related]
20. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta
Pirina P; Foschino Barbaro MP; Paleari D; Spanevello A
Respir Med; 2018 Oct; 143():74-81. PubMed ID: 30261996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
